Apparent interaction between telaprevir and warfarin in a patient with chronic hepatitis C viral infection

American Journal of Health-System Pharmacy

Volumn 69, Issue 23, 2012, Pages 2062-2065

  Gatti, Danielle C ^a   Cha, Agnes ^a,b,c  

^a BROOKLYN HOSPITAL CENTER   (United States)

^b HIV Ambulatory Care   (United States)

^c LONG ISLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENALAPRIL MALEATE; METOPROLOL; PEGINTERFERON ALPHA2A; RIBAVIRIN; TELAPREVIR; VIRUS RNA; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; DRUG ANTAGONISM; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MONITORING; HEPATITIS C; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PRIORITY JOURNAL; RETREATMENT; SIDE EFFECT; TREATMENT WITHDRAWAL; VIRUS LOAD;

EID: 84869756002     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120220     Document Type: Article

References (20)

1. Hadigan C, Kottilil S. Hepatitis C virus infection and coinfection with human immunodeficiency virus: challenges and advancements in management. JAMA. 2011; 306:294-301.
2. Centers for Disease Control and Prevention. Hepatitis C information for health professionals. www.cdc.gov/hepatitis/HCV (accessed 2012 Jun 6).
3. Ashfaq UA, Javed T, Rehman S et al. An overview of HCV molecular biology, replication and immune responses. Virol J. 2011; 8:161.
4. Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011; 364:2429-38.
5. Jacobson IM, McHutchison JG, Dusheiko G et al., for the ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364:2405-16.
6. Kiser JJ, Burton JR, Anderson PL et al. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012; 55:1620-8.
7. Ghany MG, Nelson DR, Strader DB et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54:1433-44.
8. Incivek (telaprevir) package insert. Cambridge, MA: Vertex Pharmaceuticals Incorporated; 2011 May.
9. Rockey D, Caldwell S, Goodman Z et al. Liver biopsy. Hepatology. 2009; 49:1017-44.
10. University of Liverpool. Drug interaction charts. www.hiv- druginteractions.org/Interactions.aspx (accessed 2011 Sep).
11. Pegasys (peginterferon alfa-2a) package insert. South San Francisco, CA: Genentech; 2011 Sep.
12. Copegus (ribavirin) package insert. South San Francisco, CA: Genentech; 2011 Aug.
13. Coumadin (warfarin) package insert. Princeton, NJ: Bristol-Myers Squibb; 2011 Oct.
14. Chakilam A, Chavan A, Smith G et al. Telaprevir binding to isolated human plasma proteins and protein binding displacement interactions between telaprevir and warfarin. Presented at International Workshop on the Clinical Pharmacology of Hepatitis Therapy. Cambridge, MA; 2011 Jun 22-23.
15. Van Heeswijk R, Vandevoorde A, Boogaerts G et al. Pharmacokinetic interactions between antiretroviral agents and the investigational HCV protease inhibitor telaprevir in healthy volunteers [abstract 119]. Presented at 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2011 Feb 27-Mar 2.
16. Lexapro (escitalopram) package insert. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2011 May.
17. Van Heeswijk R, Boogaerts G, De Paepe E et al. The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. Proceedings of 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Boston, MA; 2010 Jun 23-24.
18. Adachi Y, Yokoyama Y, Nanno T et al. Potentiation of warfarin by interferon. BMJ. 1995; 311:292.
19. Schulman S. Inhibition of warfarin activity by ribavirin. Ann Pharmacother. 2002; 36:72-4.
20. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007; 41:674-80.